Canada House Wellness Group Inc. announced that its wholly owned subsidiary, Abba Medix Corp. (“Abba“), has introduced Orange Dreamer and Cinnamon Twist, two indica dominant hybrid phenotypes screened in-house at Abba, to its product portfolio. Abba’s product offering now consists of seven strains. The new strains are available for immediate sale to registered Abba patients at www.abbamedix.com. Profiles for all seven available strains can also be found under the “Products” tab on Abba’s website.
“As our medical patient base continues to grow, we will listen to their needs to ensure we build a full spectrum offering of diverse strains that meet their health and wellness needs,” said Michael Orrbrooke, Abba’s President and the Chief Revenue Officer of Canada House. “In addition to sourcing and phenotyping strains that our patients covet, we continue to focus on offering our products in new formats to further meet our patient’s needs.”
“A key strategy in Canada House’s Path to Profitability is to increase Abba’s high-value medical patient base,” said Canada House CEO Chris Churchill-Smith. “Increasing our selection of cannabis products is paramount to servicing our patients while executing on this strategy.”
Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.